PLBIO(SZ:000403) Shang Hai Zheng Quan Bao·2026-02-04 19:19Core Viewpoint - The company has received a drug registration application acceptance notice for its product, Human Coagulation Factor IX, which is aimed at treating patients with Hemophilia B and is expected to enhance its product line and core competitiveness in the long term [1][4]. Group 1: Drug Information - The drug, Human Coagulation Factor IX, is an injectable formulation with a specification of 500 IU per bottle, intended for domestic production [1]. - It is indicated for patients with congenital Factor IX deficiency or those with low Factor IX levels due to other reasons, significantly improving their Factor IX levels to prevent and treat bleeding [2]. - The company aims to develop high-recovery rate blood-derived products, addressing the long-term clinical drug shortages for Hemophilia B patients [2]. Group 2: Approval Process - The company has received the acceptance notice for the drug registration, but it still requires approval from the National Medical Products Administration before it can be marketed [3]. - The company previously announced the receipt of a clinical trial approval notice for the same drug, indicating progress in the regulatory process [3]. Group 3: Impact on the Company - The receipt of the drug registration acceptance notice will not impact the company's current performance but is expected to enrich its product line and optimize product structure in the long term [4]. - This development is anticipated to enhance the comprehensive utilization rate of raw plasma and improve profitability, thereby strengthening the company's core competitiveness [4].